YTD and Q3 2022 Results
AstraZeneca PLC 10 November 2022 07:00 GMT YTD and Q3 2022 results Record number of regulatory approvals and guidance uplift underpinned by strong business performance Revenue and EPS summary YTD 2022 Q3 2022 % Change % Change $m Actual CER[1] $m Actual CER - Product Sales 32,200 29 35 10,590 9 16 - Collaboration Revenue 944 >2x